FOLH1 and prostate carcinoma: Although this target is still under investigation, clinical trials phase I exhibited parallel safety and toxicity profiles and suggest its clinical activity against MM.450–452 In addition, CAR-T has been shown to target prostate cancer through directing CAR-T cells against prostate-specific membrane antigen (PSMA) and displayed an acceptable safety and efficacy profile.453 In a phase I clinical study, Yao Wang et al.454 targeted patients with CD133-positive and late-stage metastasis malignancies by CAR-T cells in which three patients exhibited partial remission and 14 achieved stable disease.